MediPharm Labs Corp (MEDIF)

[FUNMAN]

IMO the following/referenced article sounded as if it was a PR piece giving would be suitors a reason the PPS should be supported. Or more realistically, that investors should buy it because it is an ideal M&A target.

"Long" shareholders knew the whole story.

The original business plan was a bust.

Note the difference to Valens. They adjusted on the fly by introducing their own line of products, while continuing the pursuit of their long term Canada-first plan including 2.0 product development (they announced the purchase of bought POMMIES CIDER CO on Nov 11, 2019).

https://thevalenscompany.com/press-releases/valens-establishes-operations-in-the-greater-toronto-area-with-the-acquisition-of-pommies-cider-co/

MediPharm seemed totally unprepared without a "what-if-it-doesn't-work" Plan B. They had nothing to pivot to. They rushed their own products out and only had the international plan to bank on. The tolling business concept was dead.

Finally, MediPharm's international business may be initiating some traction. Of the 30 international contracts, most are only placing their initial orders in Q4 2020 and Q1 2021.

At a minimum I am hoping Q4 2020 is a 100% sequential QoQ revenue bump with good guidance. That might stimulate belief that MediPharm is walking-the-international-walk, and spur the PPS above $1.


https://seekingalpha.com/article/4408211-medipharm-labs-undiscovered-gem-in-cannabis-sector?mail_subject=medif-medipharm-labs-undiscovered-gem-in-the-cannabis-sector&utm_campaign=rta-stock-article&utm_content=link-0&utm_medium=email&utm_source=seeking_alpha